Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme

Ruohan Sun†, Yujun Pan†, Long Mu2, Yaguang Ma2, Hong Shen2* and Yu Long2*

1Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin, China, 2Department of Neurosurgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China

Purpose: Glioblastoma multiforme (GBM) is the most widely occurring brain malignancy. It is modulated by a variety of genes, and patients with GBM have a low survival ratio and an unsatisfactory treatment effect. The irregular regulation of RNA binding proteins (RBPs) is implicated in several malignant neoplasms and reported to exhibit an association with the occurrence and development of carcinoma. Thus, it is necessary to build a stable, multi-RBPs signature-originated model for GBM prognosis and treatment response prediction.

Methods: Differentially expressed RBPs (DERBPs) were screened out based on the RBPs data of GBM and normal brain tissues from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression Program (GTEx) datasets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses on DERBPs were performed, followed by an analysis of the Protein-Protein Interaction network. Survival analysis of the DERBPs was conducted by univariate and multivariate Cox regression. Then, a risk score model was created on the basis of the gene signatures in various survival-associated RBPs, and its prognostic and predictive values were evaluated through Kaplan-Meier analysis and log-rank test. A nomogram on the basis of the hub RBPs signature was applied to estimate GBM patients’ survival rates. Moreover, western blot was for the detection of the proteins.

Results: BICC1, GNL3L, and KHDRBS2 were considered as prognosis-associated hub RBPs and then were applied in the construction of a prognostic model. Poor survival results appeared in GBM patients with a high-risk score. The area under the time-dependent ROC curve of the prognostic model was 0.723 in TCGA and 0.707 in Chinese Glioma Genome Atlas (CGGA) cohorts, indicating a good prognostic model. What was more, the survival duration of the high-risk group receiving radiotherapy or temozolomide chemotherapy was shorter than that of the low-risk group. The nomogram showed a great discriminating capacity for GBM, and western blot experiments demonstrated that the proteins of these 3 RBPs had different expressions in GBM cells.

Conclusion: The identified 3 hub RBPs-derived risk score is effective in the prediction of GBM prognosis and treatment response, and benefits to the treatment of GBM patients.

Keywords: glioblastoma multiforme, RNA binding proteins, overall survival, risk score model, prognostic model
INTRODUCTION

As the most widespread malignant neoplasm in human brain, glioblastoma multiforme (GBM) has retained a severe incidence ratio and prognosis (Johnson et al., 2013; Davis, 2016). Even though therapeutic methods to GBM diagnosis and treatment are continually ameliorating, which includes surgical resection, temozolomide (TMZ) chemotherapy and radiotherapy, average survival of 15 months remains unsatisfactory (Kim et al., 2018; Ramos et al., 2018). Presently, diagnosis of GBM mainly relies on examination of histopathology, neoplasm molecular biomarkers and imaging assessments, which is certainly not applicable to early diagnosis (Batash et al., 2017). Thus, to improve the treatment effects and life quality of patients, more knowledge of GBM molecular mechanism is needed to create efficient approaches for early detection.

RNA binding proteins (RBPs) refer to the proteins that interact with several RNAs, and participate in most post-transcriptional modulation processes and cellular homeostasis (Hentze et al., 2018; Gebauer et al., 2020). RBPs mediate the modulation of RNA splicing, polyadenylation, stability, localization, translation, and degradation via binding to targeted RNAs and then forming ribonucleoprotein complexes (Wende et al., 2019). Taking post-transcriptional modulation into consideration, no doubt abnormally dysregulated RBPs are intimately associated with the incidence and development of many diseases, such as cancers (Pereira et al., 2017; Neelamraju et al., 2018). Recently, some researchers uncover that RBPs facilitate tumorigenesis not only by raising oncogene levels, but also by reducing tumor suppressor gene levels (Guo and Jia, 2018; Zhang et al., 2018). Therefore, a lot of attention has turned to the roles of RBPs in cancers.

It is reported that RBPs present a close relationship to glioma’s occurrence and development (Xu et al., 2018; Yi et al., 2018). For example, the expression of PCBP2 is dramatically increased at a higher stage of glioma. Ablating PCBP2 greatly decreases the colony formation and invasion capability of GBM cells (Han et al., 2013; Luo and Zhuang, 2017). HuR is overexpressed in high-grade malignancies (GBM and medulloblastoma). Additionally, HuR could bind and stabilize mRNAs of growth factors that are associated with the progression of brain neoplasm (Nabors et al., 2001). In glioma and medulloblastoma, MS11 expression is significantly elevated (Kanemura et al., 2001). Based on these findings, we attempt to systematically investigate RBPs’ functions to understand their roles in GBM.

In current years, data mining and bioinformatics analysis have been largely applied in research on carcinomas. A large number of high-throughput data produced by microarrays and next-generation sequencing are gathered in public datasets. Among them, The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) get extensively adopted. Exploration of tumor expression features and identification of prognostic indicators and biomarkers can be greatly aided by mining these data. Based on the methylation array data in TCGA dataset, Rajendra P. Pangeni et al. analyzed tumor subtype-associated epigenetic regulation in GBM bulk tumors using genome-wide methylation and transcription (Pangeni et al., 2018). Based on the Gene Expression Omnibus (GEO) database, Huiwen Gui et al. used bioinformatics analysis to determine that GAPDH, RHOA, RPS29, and RSS27A are the hub genes of Alzheimer’s disease (Gui et al., 2021).

Here, our study is to carry out a comprehensive analysis of GBM in TCGA and CGGA to determine the survival-related differentially expressed RBPs (DERBPs), and used a series of bioinformatics analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Protein-Protein Interaction (PPI), to get the hub RBPs and key pathways in GBM. Based on the selected hub RBPs and public data, we establish a risk model for prognosis and treatment response prediction.

MATERIALS AND METHODS

Data Acquisition

We obtained 1,092 normal brain tissue samples of 201 individuals from the Genotype-Tissue Expression Program (GTEX, https://www.gtexexportal.org/home/datasets), 153 GBM samples with relevant clinical data from TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga), and 85 GBM samples with relevant clinical data from CGGA cohort (https://www.cgga.org.cn/download.jsp). 1542 RBPs were extracted from the above-mentioned 3 RNA-sequencing data cohorts (Li et al., 2020a). DERBPs were determined by the negative binomial distribution method between a normal brain and GBM tissues. Besides, the Limma package (http://www.bioconductor.org/packages/release/bioc/html/limma.html) was carried out here on the basis of the negative binomial distribution. It fits a universal linear gene model and utilizes empirical Bayes shrinkage for the assessments of interspersion and fold change (FC). We preprocessed original data by Limma package and ruled out genes with a mean value <1. Additionally, the DERBPs got determined by the Limma package with the standard criteria of $|\log_2 FC| \geq 1$ and false discovery rate (FDR) < 0.05.

KEGG Pathway and GO Enrichment Analyses

GO and KEGG got employed to evaluate the DERBPs’ biological functions. CC (cellular component), MF (molecular function) and BP (biological process) were the main classifications of GO. The clusterProfiler package in R participated in all enrichment analyses (Yu et al., 2012). Statistical significance was defined as p and FDR values <0.05.

Construction of Protein-Protein Interaction Network

The DERBPs were input to the STRING database (Search Tool for the Retrieval of Interaction Gene, http://www.string-db.org/) (Li et al., 2020a) to determine PPI data. The construction and
visualization of PPI networks were performed by Cytoscape 3.7.0 software.

**Prognostic Model Construction**

To assess whether the DERBPs had an association with survival, univariate Cox proportional hazards regression analysis was carried out in TCGA GBM cohort for overall survival (OS). Then, the hub RBPs related to survival were further identified using multivariate Cox proportional hazards regression among candidate genes.

According to the gene signatures of survival-related hub RBPs determined by multivariate Cox proportional hazards regression, we established a risk score model as the formula described below.

\[
\text{Risk score} = \sum_{i=1}^{n} \beta_i \times E_i
\]

“n” represents key RBPs number in total; “\( \beta_i \)” indicates gene i ’s regression coefficient; “\( E_i \)” represents the gene i ’s expression value. In the validation CGGA dataset, “\( \beta_i \)” used was the same as that in the TCGA.

For exploring the prognosis and prediction abilities of risk score, we classified GBM patients into high- and low-risk groups on account of the median risk score survival analysis. Kaplan-Meier (KM) method with the log-rank test was conducted for the survival rate analyses of the two groups. Clinicopathological parameters and risk scores were analyzed through univariate and multivariate Cox regressions to ensure that risk scores possessed significance in clinical. In addition, the SurvivalROC (receiver operating characteristic) package completed the ROC curve analysis to evaluate the above model’s prognostic ability (Heagerty et al., 2000). A validation cohort of 85 GBM patients with responsible prognosis from CGGA was employed to confirm the prognostic model’s predictive capability. Lastly, RMS R package was utilized to generate the nomogram including calibration plots to predict OS.

**GBM Tissue Samples**

The resected neoplasm specimens of two GBM patients were obtained from the Department of Neurosurgery, the First Affiliated Hospital of Harbin Medical University. Histological grading got classified according to WHO criteria. This experiment got the permission of the Institutional Review Board of Harbin Medical University, and written informed consent was signed by every patient. GBM-1 and GBM-2 cells were derived from patient fresh GBM specimens.

**Human Cell Lines**

HEB (normal human glial cell) and U-87 MG (GBM cell) cells were kindly provided by Prof. Qian He (Shenzhen People’s Hospital, Shenzhen, China), all GBM cells were cultivated in DMEM with 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml) in a 37°C environment containing 5% CO2.

**Western Blot**

Tissue and cellular proteins were extracted using tissue extraction buffer and RIPA buffer with protease inhibitor cocktail (Sigma, P8340), respectively. SDS-PAGE was used to separate equal quantities of protein which was then transferred to nitrocellulose membranes. Antibodies applied here were listed as follows: anti-BICC1 (Sigma, HPA045212), anti-GNL3L (Sigma, SAB4502257), anti-KHDRBS2 (ThermoFisher Scientific, PA5-96508), anti-β-Actin (Sigma, A1978) and horseradish peroxidase-conjugated anti-rabbit/mouse IgG (Cell Signaling, 7074 and 7076). Compared with β-Actin, the expressions of target proteins were calculated and then generalized to the equivalent expressions in HEB cells.

**Statistical Analysis**

The representative data were derived from five separate experiments and shown as the mean ± SEM. Graphpad Prism 7.0 or R software (https://www.r-project.org/) was adopted for statistical analysis. Unpaired Student’s t-tests with Mann-Whitney U tests and one-way ANOVA with Kruskal-Wallis H tests were used to examine differences between two or more groups. The correlation of risk score with clinicopathological parameters was studied by Pearson Chi-Square test and Fisher’s exact test. The log-rank test was for the statistical significance evaluation of the differences in each dataset, and the KM technique was used to create survival curves for the subgroups in each dataset. \( p < 0.05 \) indicated significance in statistics.

**RESULTS**

**Analysis of the DERBPs in Patients With GBM**

The crucial prognosis role of RBPs in GBM was comprehensively studied by several advanced computational methods. Supplementary Figure S1 showed our study design. The GBM dataset (TCGA) contained 153 tumor samples in comparison to 1,092 normal brain samples (GTEx Portal). All derived data from the two datasets were preprocessed by the R software packages. In total, 1542 RBPs were analyzed and 160 RBPs were retained, consisting of 52 RBPs with upregulation and 108 RBPs with downregulation (Figure 1). Our data indicated GBM existed various DERBPs in comparison with normal brain tissues.

**Functional Enrichment Analysis of the DERBPs**

The DERBPs comprised two groups of upregulation and downregulation. We conducted functional enrichment analysis of the two groups by GO and KEGG. Regarding GO analysis, BP, CC, and MF terms were applied to annotate these DERBPs’ functions. BP analysis demonstrated DERBPs with upregulation were primarily associated with defense response to viruses, RNA catabolic processes and RNA phosphodiester bond hydrolysis (Figure 2A), and that the DERBPs with downregulation were mainly related to the regulation of RNA splicing, RNA splicing and mRNA metabolic process (Figure 2B). By the CC analysis, both upregulated and downregulated DERBPs were enriched in
total ribonucleoprotein granules and cytoplasmic ribonucleoprotein granules (Figure 2). MF analysis results showed DERBPs with upregulation were associated with catalytic activity acting on RNA, double-stranded RNA binding and mRNA 3'-UTR binding (Figure 2A), while those with downregulation were largely linked with catalytic activity acting on RNA, mRNA 3'-UTR binding and translation regulator activity (Figure 2B). The KEGG analysis demonstrated DERBPs with upregulation were significantly related to influenza A, mRNA surveillance pathway, ribosome biogenesis in eukaryotes and RNA transport. And those with downregulation were significantly associated with RNA transport, mRNA surveillance pathway, and RNA polymerase degradation (Table 1).

![Image](image_url)
Selection of RBPs Related to Prognosis

In order to study the pivotal DERBPs in GBM, we utilized Cytoscape software to create a PPI network, containing 120 nodes and 260 edges (Supplementary Figure S2). To deeply evaluate the prognosis values of 120 RBPs, univariate Cox regression analysis of each for OS was conducted and we obtained 6 prognosis-associated candidate hub RBPs. As shown in Figures 3A, 2 RBPs displayed an inverse correlation with survival, and 4 RBPs exhibited a positive correlation with survival (p < 0.05) (Figure 3A and Table 2). Following that, multiple stepwise Cox regression was used to evaluate the influence of the 6 potential hub RBPs on patient survival time and clinical outcomes. We eventually identified 3 hub RBPs, including G Protein Nucleolar 3 Like (GNL3L), BicC Family RNA Binding Protein 1 (BICC1), and KH RNA Binding Domain Containing, Signal Transduction Associated 2 (KHDRBS2), correlating with OS (Figure 3B and Table 2). High expression of BICC1 was found in GBM and its expression was inversely correlated with survival (HR > 1). Low expression of KHDRBS2 was found in GBM and its level was positively correlated with survival (HR < 1). Of interest, expression of GNL3L was dramatically higher in GBM, but its increase in expression exhibited a positive correlation with survival (HR < 1). Our results collectively implied that these 3 hub RBPs had close relations with the OS in GBM patients.

TABLE 1 | KEGG pathway analysis of DERBPs.

| Category       | Term                              | Description                                  | p Value     | FDR          | Count |
|----------------|-----------------------------------|----------------------------------------------|-------------|--------------|-------|
| Upregulated    | Pathway hsa05164                  | influenza A                                 | 2.86221E-06 | 7.53213E-06  | 7     |
|                | Pathway hsa03015                  | mRNA surveillance pathway                    | 0.000382507 | 0.00532999   | 4     |
|                | Pathway hsa03008                  | Ribosome biogenesis in eukaryotes            | 0.000640096 | 0.007369263  | 4     |
|                | Pathway hsa05162                  | Measles                                      | 0.011824335 | 0.010607124  | 4     |
|                | Pathway hsa00970                  | Aminoacyl-tRNA biosynthesis                  | 0.002015354 | 0.010607124  | 3     |
|                | Pathway hsa03013                  | RNA transport                               | 0.00476635  | 0.020905044  | 4     |
|                | Pathway hsa04620                  | Toll-like receptor signaling pathway         | 0.007260019 | 0.02731586   | 3     |
|                | Pathway hsa05160                  | Hepatitis C                                  | 0.021283853 | 0.070012673  | 3     |
|                | Pathway hsa03018                  | RNA degradation                              | 0.03688458  | 0.107849589  | 2     |

| Downregulated  | Pathway hsa03013                  | RNA transport                               | 5.02482E-10 | 1.95703E-08  | 10    |
|                | Pathway hsa03015                  | mRNA surveillance pathway                    | 8.49691E-07 | 1.65447E-06  | 6     |
|                | Pathway hsa03020                  | RNA polymerase                              | 0.000196405 | 0.002549819  | 3     |
|                | Pathway hsa03018                  | RNA degradation                             | 0.000362616 | 0.0029820204 | 3     |
|                | Pathway hsa03008                  | Ribosome biogenesis in eukaryotes            | 0.008126664 | 0.063302434  | 3     |
|                | Pathway hsa03040                  | Spliceosome                                  | 0.017563625 | 0.10664299   | 3     |
|                | Pathway hsa05134                  | Legionellosis                                | 0.018917424 | 0.10664299   | 2     |
|                | Pathway hsa05164                  | influenza A                                 | 0.024818692 | 0.10664299   | 3     |
|                | Pathway hsa00970                  | Aminoacyl-tRNA biosynthesis                  | 0.024904555 | 0.10664299   | 2     |
|                | Pathway hsa05016                  | Huntington disease                           | 0.025840768 | 0.10664299   | 4     |

Note: Category: KEGG pathway. Count: the number of DERBPs. Abbreviations: DERBPs, differentially expressed RNA binding proteins; KEGG, Kyoto Encyclopedia of Genes and Genomes.

FIGURE 3 | Cox regression analysis in TCGA GBM cohort. (A) Univariate Cox regression analysis for identification of hub RBPs in TCGA dataset. (B) Multivariate Cox regression analysis to identify prognosis related hub RBPs.
TABLE 2 | 3 prognosis-associated hub RBPs identified by univariate and multivariate Cox regression analysis.

| Factor      | Up/Down | Univariate analysis |  | Multivariate analysis |  |
|-------------|---------|---------------------|--|----------------------|--|
|             |         | HR                 | 95% CI | p Value          | β  | HR | 95% CI | p Value          |
| BICC1       | Up      | 1.253              | 1.007–1.558 | 0.042         | 0.231 | 1.259 | 0.990–1.602 | 0.059         |
| RNASE2      | Up      | 1.059              | 1.002–1.118 | 0.039         | −0.527 | 0.669 | 0.498–0.898 | 0.007         |
| GNL3L       | Up      | 0.691              | 0.520–0.920 | 0.011         | −0.402 | 0.590 | 0.382–0.911 | 0.017         |
| KHDDRBS2    | Down    | 0.538              | 0.355–0.814 | 0.003         |        |       |          |               |
| WDR5        | Down    | 0.709              | 0.525–0.957 | 0.025         |        |       |          |               |
| MRPL38      | Down    | 0.260              | 0.069–0.979 | 0.046         |        |       |          |               |

Abbreviations: HR, hazard ratio; CI, confidence interval.

FIGURE 4 | Risk score analysis of 3-genes prognostic model in TCGA cohort. (A) OS analysis among TCGA GBM patients stratified by risk score. (B) ROC curve for forecasting OS based on risk score. (C) Expression heat map of the 3 hub RBPs. (D) Survival status of the TCGA GBM patients. (E) The risk score values in low- and high-risk subgroups. OS, overall survival.
The Survival and Treatment Response was Predicted by the 3 Hub RBPs-Derived Risk Score Model in TCGA GBM Cohort

Next, a risk score model was built according to the above 3 hub RBPs. Each patient’s risk score got acquired from the formula below:

\[ \text{Risk score} = \beta_{\text{BICC1}} \times E_{\text{BICC1}} + \beta_{\text{GNL3L}} \times E_{\text{GNL3L}} + \beta_{\text{KHDRBS2}} \times E_{\text{KHDRBS2}} \]

where “E” indicates the expression values of pertinent RBPs, and “\( \beta \)” represents the regression coefficient determined from multivariate Cox stepwise regression analysis according to the TCGA GBM cohort (Table 2). Then, we assessed predictive ability by conducting a survival analysis. TCGA GBM patients got classified into low- and high-risk subgroups with the standard of the median value. The data suggested compared with the low-risk group, the high-risk group presented an unsatisfying OS status (Figure 4A). A time-dependent ROC analysis was used to further assess the predictive capability of the 3 RBPs-derived risk model. Our data revealed RBPs risk score model’s area under the ROC curve (AUC) was 0.723 (Figure 4B), suggesting it displayed a moderate diagnosis ability. Figures 4C–E showed the expression heat maps of the 3 hub RBPs, patient survival status and the risk score of the signature comprised of 3 RBPs in the low and high-risk subgroups.

A high-risk score was strongly linked with IDH1-wild type and mesenchymal subtype, according to an analysis of the correlation between the risk score and clinicopathological features (Figures 5A,B and Supplementary Table S1). The IDH1-wild type or mesenchymal subtype GBM was linked to a bad prognosis (Supplementary Figure S3), as shown in earlier research (Yan et al., 2009; Wang et al., 2017), implying that a high-risk score might be associated with an unsatisfying prognosis.
KM survival analysis of the above two groups was performed to confirm the risk score’s prognostic relevance. Survival analysis indicated GBM patients with a high-risk score and IDH1-wild type had the worst results (Figure 5C), and in the non-mesenchymal subgroup, patients with a high-risk score had a shorter survival time than those with a low-risk score (Figure 5D). Univariate and multivariate analyses were employed to validate the prognosis significance of risk score (Supplementary Table S2). Moreover, in GBM patients suffering from radiation or TMZ chemotherapy, a high-risk score was linked to a poor result, showing the risk score might predict the treatment effects (Figures 5E,F).

The Prognosis and Treatment Response was Predicted by the Risk Score Model in CGGA GBM Cohort

To deeply confirm the prediction ability of risk score, the 3 hub RBPs-derived risk score model was assessed, and KM survival analysis got performed in CGGA dataset of GBM. It was found that those with a high-risk score got a worse OS than patients with a low-risk score (Figure 6A). The AUC of the prognostic model counted 0.707, which showed a similar result compared to AUC in TCGA cohort (Figure 6B). Figures 6C–E showed the expression heat maps of 3 hub RBPs, patient survival status, and the risk score.
of the signature comprised of 3 RBPs in low- and high-risk subgroups. We found that compared to GBM patients with IDH1-mutation and a low-risk score, those with IDH1-mutation and a high-risk score tended to have a poor outcome, while no obvious survival difference was observed in GBM patients with a high-risk or low-risk score in the IDH1-wild type subgroup (Figure 7A), probably because of tumor heterogeneity and small sample size. Similarly, in comparison with non-mesenchymal GBM patients having low-risk scores, those having high-risk scores had worse survival time (Figure 7B). Finally, a high-risk score was linked with bad results in GBM patients undergoing radiotherapy or TMZ chemotherapy (Figures 7C,D). Collectively, these findings suggested the risk score model could forecast GBM patients’ prognosis and therapy evaluation.

**Nomogram Design on the Basis of the Hub RBPs**

3 RBPs signatures were combined for nomogram construction to create a predictive estimation approach (Figure 8). According to the multivariate Cox analysis, points were distributed to respective variables through the nomogram scale. A horizontal line was drawn for each variable with demarcations for the number of points, the whole points were counted for each patient and generalized to a range of 0–100. The evaluated survival rates of GBM patients could be determined by drawing a vertical line from the total point axis to each prognosis axis in the next 3 years. This nomogram would facilitate the clinical treatment for GBM patients.

![Figure 7](image-url)
Validating the Differentially Expressed 3 Hub RBPs in GBM Cells

To confirm the dysregulated expressions of the 3 hub RBPs (BICC1, GNL3L, and KHDRBS2) in GBM, western blot was carried out to measure their protein levels in GBM cells and normal glial cells. Figure 9 indicated BICC1 and GNL3L were upregulated in GBM cells, while KHDRBS2 was downregulated.

DISCUSSION

GBM is featured with complicated background on the molecular level (Reifenberger et al., 2016), while high-throughput data on GBM studies makes it easier to find the molecular diagnosis and prognosis biomarkers. In our context, we comprehensively investigated the DERBPs of GBM from TCGA and GTEx cohorts, and uncovered 3 hub RBPs (BICC1, GNL3L, and...
KHDRBS2) abnormally expressing in GBM. The risk score model originated from the 3 hub RBPs exhibited vital functions in the prediction of GBM patients’ prognosis and treatment response.

Firstly, we screened for the GBM DERBPs through RNA sequencing data from TCGA and GTEx datasets, rather than only TCGA. The normal brain tissue samples in TCGA were acquired from tissues surrounding tumors, which couldn’t represent normal brain tissue samples completely. The GTEx dataset contained 1,092 samples of 11 brain regions from 201 normal individuals (Consortium, 2015; Mu et al., 2019). In this way, the discovered RBPs (52 upregulated and 108 downregulated) might surely have a stable and particular expression in GBM than that in normal control. We built co-expression and PPI networks for these RBPs by thoroughly studying key biological pathways. Next, we discovered that BICCI, GNL3L, and KHDRBS2 levels were associated with survival by univariate and multivariate Cox regression analysis. Among them, upregulated BICCI exhibited a negative correlation with survival, indicating it functioned as an oncogene. Downregulated KHDRBS2 displayed a positive correlation with survival, so it might function as a tumor suppressor gene in GBM. Of note, expression of GNL3L was considerably higher in GBM while being positively correlated with survival, so GNL3L was an indicator of lower risk in GBM (HR < 1). In addition, western blot analysis confirmed that the 3 hub RBPs were differentially expressed in GBM cells. As a result, the risk score model was created using the signature of the 3 hub RBPs.

According to prior research, regulation of translation, RNA processing and RNA metabolism are all linked to the incidence and progression of a range of human diseases (Subramanian and Simon, 2016; Caffarel and Coleman, 2014; Reifenberger et al., 2016). In our study, the functional enrichment analysis indicated the abnormal RBPs governed the carcinogenesis and development of GBM via the mRNA surveillance pathway, RNA degradation, ribosome synthesis, and RNA degradation. Although most connections between RBPs and tumors remain confusing, there are still some findings of them (Wang et al., 2018). For instance, PTBP1 can enhance glioma proliferation and migration by increasing the inclusion of exon 3 in RTN4 mRNA (Cheung et al., 2009). HNRNPA2B1 promotes glioma development and aggressiveness (Golan-Gerstl et al., 2011). PTRF, alias Cavin1, is recognized as a non-canonical RBP in GBM and is also identified as a prognosis-related factor (Huang et al., 2018; Wang et al., 2020a). In addition, FNDC3B, a membrane protein, not only promotes migration and invasion of glioma cells, but can also act as a prognostic biomarker (Fischer et al., 2017; Wang et al., 2020a). SLC25A43, a molecular marker, is also proved to be related to a poor prognosis in GBM (Haitina et al., 2006; Wang et al., 2020a).

Herein, the 3 hub RBPs-derived risk score performed well in predicting the GBM patients’ survival status in TCGA, and their prognosis functions could be reproduced in CGGA. According to the ROC curve study, the 3 RBPs signatures had the diagnosis ability to determine the GBM patients with a bad prognosis. The constructed nomogram facilitated the OS prediction in the following 3 years more quantitatively. In addition, the risk score model could forecast the treatment effects of GBM patients undergoing radiotherapy or chemotherapy. Therefore, a prospective risk score model derived from multi-RBPs signature was established, which could be utilized as a biomarker for GBM’s prognosis and prediction.

Among the 3 hub RBPs, BICC1 is implicated in the post-transcriptional regulation of mRNA (Rothé et al., 2015; Davidson et al., 2016). Inhibition of BICC1 expression can promote cell apoptosis and suppress cell proliferation in tumor cells (Wang et al., 2020b). GNL3L, HSR1-MMR1 family, is a putative nucleolar GTPase existing throughout eukaryotes (Thoompumkal et al., 2016). GNL3L has been discovered as a factor involved in the maintenance of the tumorigenic properties of tumor-initiating cells (Kannathasan et al., 2020). Moreover, GNL3L may enhance NF-κB-regulated tumor cell viability via the upregulation of antiapoptosis-related genes (Thoompumkal et al., 2015; Kannathasan et al., 2020). However, no previous study has assessed the effects of GNL3L in GBM. As for KHDRBS2, although the relation of KHDRBS2 overexpression to better OS in lung adenocarcinoma is well understood (Li et al., 2020b), little is known about it in GBM. The biological activities of these 3 hub RBPs have offered some insight into the value of risk score in GBM prognosis and prediction, but more research of them in GBM development and the potential mechanisms is needed.

The risk score’s applicable efficacy may be beneficial for directing treatment options to improve the clinical outcome of GBM patients. Patients with high-risk scores should accept aggressive treatment, while those with low-risk scores should avoid excessive therapies that might result in unwanted side effects. As a result, it is critical to put the risk score into clinical practice that is guaranteed by promising research to deeply confirm the value of risk score in GBM prediction and prognosis.

This study has some limitations. First, the number of clinical samples used to verify 3 hub RBPs is not large enough. Secondly, the biological functions of these 3 RBPs in GBM need to be further explored. Finally, the clinical application value of risk scores remains to be further verified.

Our systematic exploration of DERBPs through a sequence of bioinformatics analyses in GBM, and identified a total of 160 DERBPs (52 upregulated and 108 downregulated). The results of functional analysis showed that RBPs are mainly involved in mRNA surveillance pathway, RNA degradation, ribosome synthesis, and RNA degradation. Univariate and multiple COX regression analysis showed that BICCI, GNL3L, and KHDRBS2 are related to the prognosis of GBM patients. A risk score model was constructed based on the differential expressions of 3 hub RBPs. In addition, we analyzed the expression levels of 3 hub RBPs in GBM tissues and cell lines. This risk score model performs favorably in the prediction of GBM patients’ therapy and prognosis, which potentially optimizes treatment decisions.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by this experiment got the permission of Institutional Review Board of Harbin Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Conception and design: RS, YP, and YL. Development of methodology: HS and RS. Sample collection: YP, LM, and HS. Analysis and interpretation of data: RS and YM. Writing, review, and/or revision of the manuscript: RS, YP, and YL.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 82002644 and 82001131), the Natural Science Foundation of Heilongjiang Province (Grant No. YQ2021H018 and LH2019H082), Outstanding Medical Fund for Young Scholar of the First Affiliated Hospital of Harbin Medical University (Grant No. HYD2020YQ0016 and HYD2020YQ0022), Medical and Health Research Program of Heilongjiang Province (Grant No. 2020-129), Young Innovative Talents Fund of the Regular Institutions of Higher Education of Heilongjiang Province (Grant No. UNPYSCT-2020158) and the Heilongjiang Postdoctoral Foundation (Grant No. LBH-Z19189).

ACKNOWLEDGMENTS

The results of this study are based on the data from TCGA, CGGA, and GTEx databases. We thank the authors who provided the data for this study. We would like to thank Prof. Qian He (Shenzhen People’s Hospital, Shenzhen, China) for his assistance with the normal human glial cell line (HEB) and GBM cell line (U-87 MG). We also thank Alicia Hou (University of Florida, Jacksonville, Florida, United States) for her language editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.768930/full#supplementary-material

REFERENCES

Batash, R., Asna, N., Schaffer, P., Francis, N., and Schaffer, M. (2017). Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. Curr. Med. Chem. 24 (27), 3002–3009. doi:10.2174/0929867324666170516123206

Caffarel, M. M., and Coleman, N. (2014). Oncostatin M Receptor Is a Novel Therapeutic Target in Cervical Squamous Cell Carcinoma. J. Pathol. 232 (4), 386–390. doi:10.1002/path.4305

Cheung, H. C., Hai, T., Zhu, W., Baggerly, K. A., Tsavachidis, S., Krahe, R., et al. (2009). Splicing Factors PTBP1 and PTBP2 Promote Proliferation and Migration of Glioma Cell Lines. Brain. 132 (Pt 8), 2277–2288. doi:10.1093/brain/awp153

Consortium, G. T. (2015). Human Genomics. The Genotype-Tissue Expression (GTEx) Pilot Analysis: Multitissue Gene Regulation in Humans. Science. 348 (6235), 648–660. doi:10.1126/science.1262110

Davidson, S., Shanley, L., Cowie, P., Lear, M., McGuinness, P., Quinn, J. P., et al. (2016). Analysis of the Effects of Depression Associated Polymorphisms on the Activity of the BIC11 Promoter in Amygdala Neurons. Pharmacogenomics J. 16 (4), 366–374. doi:10.1038/tpg.2015.62

Davis, M. E. (2016). Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 20 (3 Suppl. 1), S2–S8. doi:10.1186/1866-321-8

Fischer, K., Al-Sawaf, O., Fink, A.-M., Dixon, M., Bahlo, J., Warburton, S., et al. (2017). Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukemia. Blood. 129 (19), 2702–2705. doi:10.1182/blood-2017-01-761973

Gebauer, F., Schwarzl, T., Valcárcel, J., and Hentze, M. W. (2020). RNA-Binding Proteins in Human Genetic Disease. Nat. Rev. Genet. 22 (3), 185–198. doi:10.1038/s41576-020-0032-y

Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.-S., Bakács, A., Coppola, L., et al. (2011). Splicing Factor HnRNPA2/B1 Regulates Tumor Suppressor Gene Splicing and Is an Oncogenic Driver in Glioblastoma. Cancer Res. 71 (13), 4464–4472. doi:10.1158/0008-5472.can-10-4410

Gui, H., Gong, Q., Jiang, J., Liu, M., and Li, H. (2021). Identification of the Hub Genes in Alzheimer’s Disease. Comput. Math. Methods Med. 2021, 6329041. doi:10.1155/2021/6329041

Guo, J., and Jia, R. (2018). Splicing Factor Poly(rC)-Binding Protein 1 Is a Novel and Distinctive Tumor Suppressor. J. Cell Physiol. 234 (1), 33–41. doi:10.1002/jcp.26873

Haitinas, T., Lindblom, J., Renström, T., and Fredriksson, R. (2006). Fourteen Novel Human Members of Mitochondrial Solute Carrier Family 25 (SLC25) Widely Expressed in the Central Nervous System. Genomics. 88 (6), 779–790. doi:10.1016/j.ygeno.2006.06.016

Han, W., Xin, Z., Zhao, Z., Bao, W., Lin, X., Yin, B., et al. (2013). RNA-Binding Protein PCBP2 Modulates Glioma Growth by Regulating FHL3. J. Clin. Invest. 123 (5), 2103–2118. doi:10.1172/jci61820

Heagerty, P. J., Lumley, T., and Pepe, M. S. (2000). Time-Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker. Biometrics. 56 (2), 337–344. doi:10.1111/j.0006-341x.2000.00337.x

Hentze, M. W., Castello, A., Schwarzl, T., and Preiss, T. (2018). A Brave New World of RNA-Binding Proteins. Nat. Rev. Mol. Cell Biol. 19 (5), 327–341. doi:10.1038/nrm.2017.130

Huang, K., Fang, C., Yi, K., Liu, X., Qi, H., Tan, Y., et al. (2018). The Role of PTRF/PROCR1 in Neuronal Differentiation. Brain. 132 (Pt 8), 2277–2288. doi:10.1172/jci61820

Johnson, D. R., Leeper, H. E., and Uhm, J. H. (2013). Glioblastoma Survival in the United States Improved After Food and Drug Administration Approval of Bevacizumab: a Population-Based Analysis. Cancer. 119 (19), 3489–3495. doi:10.1002/cncr.28259

Kenemura, Y., Mori, K., Sakakibara, S., Fujikawa, H., Hayashi, H., Nakano, A., et al. (2001). Musashi, an Evolutionarily Conserved Neural RNA-Binding Protein, Is a Versatile Marker of Human Glioma Cells in Determining Their Cellular Origin, Malignancy, and Proliferative Activity. Differentiation. 68 (2-3), 141–152. doi:10.1046/j.1432-0436.2001.680208.x

Kanemura, Y., Mori, K., Sakakibara, S., Fujikawa, H., Hayashi, H., Nakano, A., et al. (2001). Musashi, an Evolutionarily Conserved Neural RNA-Binding Protein, Is a Versatile Marker of Human Glioma Cells in Determining Their Cellular Origin, Malignancy, and Proliferative Activity. Differentiation. 68 (2-3), 141–152. doi:10.1046/j.1432-0436.2001.680208.x
Kannathasan, T., Kuo, W. W., Chen, M. C., Viswanadha, V. P., Shen, C. Y., Tu, C. C., et al. (2020). Chemoresistance-Associated Silenting of miR-4554 Promotes Colorectal Cancer Aggression through the GNL3L and NF-Kb Pathway. *Cancers* (Basel). 12 (5). doi:10.3390/cancers12051231

Kim, M. M., Umemura, Y., and Leung, D. (2018). Bevacizumab and Glioblastoma. *Cancer J*. 24 (4), 180–186. doi:10.1097/PPO.0000000000000326

Li, W., Gao, L.-N., Song, P.-P., and You, C.-G. (2020a). Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Lung Adenocarcinoma. *Aging*. 12 (4), 3558–3573. doi:10.18632/aging.102828

Li, W., Li, N., Gao, L., and You, C. (2020b). Integrated Analysis of the Roles and Prognostic Value of RNA Binding Proteins in Lung Adenocarcinoma. *Peer. R.*. e8509. doi:10.7717/peerj.8509

Luo, K., and Zhang, K. (2017). High Expression of PCBP2 Is Associated With Progression and Poor Prognosis in Patients With Glioblastoma. *BioMed. Pharmacother.*. 94, 659–665. doi:10.1016/j.biopha.2017.07.013

Mu, Q., Chen, Y., and Wang, J. (2019). Deciphering Brain Complexity Using Single-Cell Sequencing. *Genomics Proteomics Bioinformatics*. 17 (4), 344–366. doi:10.1016/j.gpb.2018.07.007

Nabors, L. B., Gillespie, G. Y., Harkins, L., and King, P. H. (2011). HuR, a RNA Stability Factor, Is Expressed in Malignant Brain Tumors and Binds to Adenine- and Uridine-Rich Elements Within the 3’ Untranslated Regions of Cytokine and Angiogenic Factor mRNAs. *Cancer Res*. 61 (5), 2154–2161. doi:10.1158/0008-5472.CAN-09-4043

Neeleswaru, Y., Gonzalez-Perez, A., Bhat-Nakshatri, P., Nakshatri, H., and Janga, S. C. (2018). Mutational Landscape of RNA-Binding Proteins in Human Cancers. *RNA Biol.* 15 (1), 115–129. doi:10.1080/15476286.2017.1391436

Pangeni, R. P., Zhang, Z., Alvarez, A. A., Wan, X., Saxtry, N., Lu, S., et al. (2018). Genome-Wide Methyliconic and Transcriptomic Analyses Identify Subtype-Specific Epigenetic Signatures Commonly Dysregulated in Glioma Stem Cells and Glioblastoma. *Epigenetics*. 13 (4), 432–448. doi:10.1080/15592294.2018.1469892

Pereira, B., Billaud, M., and Almeida, R. (2017). RNA-Binding Proteins in Cancer: Old Players and New Actors. *Trends Cancer*. 3 (7), 506–528. doi:10.1016/j.trecan.2017.05.003

Ramos, A. D., Magge, R. S., and Ramakrishna, R. (2018). Molecular Pathogenesis and Emerging Treatment for Glioblastoma. *World Neurosurg.*. 116, 495–504. doi:10.1016/j.wneu.2018.04.021

Reifenberger, G., Wirsching, H. G., Knobbe-Thomsen, C. B., and Weller, M. (2016). Advances in the Molecular Genetics of Gliomas - Implications for Classification and Therapy. *Nat. Rev. Clin. Oncol.*. 13, 443–452. doi:10.1038/nrclinonc.2016.204

Rothe, B., Leal-Esteban, L., Bernet, F., Urfur, S., Doerr, N., Weimbs, T., et al. (2015). BicC1 Polymerization Regulates the Localization and Silencing of Bound mRNA. *Mol. Cell Biol.* 35 (19), 3339–3353. doi:10.1128/mcb.00341-15

Subramanian, J., and Simon, R. (2010). What Should Physicians Look for in Evaluating Prognostic Gene-Expression Signatures? *Nat. Rev. Clin. Oncol*. 7 (6), 327–334. doi:10.1038/nrclinonc.2010.60

Thompsonkula, I. J., Rehana, K., Anbarasu, K., and Mahalingam, S. (2016). Leucine Zipper Down-Regulated in Cancer-1 (LDOCl) Interacts With Guanine Nucleotide Binding Protein-Like 3-Like (GNL3L) to Modulate Nuclear Factor-Kappa B (NF-Kb) Signaling During Cell Proliferation. *Cell Cycle*. 15 (23), 3251–3267. doi:10.1080/15384101.2016.1242534

Thompsonkula, I. J., Subba Rao, M. R. K., Kumaraswamy, A., Krishnan, R., and Mahalingam, S. (2015). GNL3L Is a Nucleo-Cytoplasmic Shutting Protein: Role in Cell Cycle Regulation. *PLoS One*. 10 (8), e0135845. doi:10.1371/journal.pone.0135845

Wang, Z., Tang, W., Yuan, J., Qiang, B., Han, W., and Peng, X. (2020a). Integrated Analysis of RNA-Binding Proteins in Glioma. *Cancers* (Basel). 12 (4), 892. doi:10.3390/cancers12040892

Wang, H., Guo, Y., Mi, N., and Zhou, L. (2020b). miR-101-3p and miR-199b-5p Promote Cell Apoptosis in Oral Cancer by Targeting BICC1. *Mol. Cell Probes*. 52, 101567. doi:10.1016/j.mcp.2020.101567

Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpone, L., et al. (2017). Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates With Immunological Changes in the Microenvironment. *Cancer Cell*. 32 (1), 42–56. doi:10.1016/j.ccell.2017.08.003

Wang, Z.-L., Li, B., Luo, Y.-X., Lin, Q., Liu, S.-R., Zhang, X.-Q., et al. (2018). Comprehensive Genomic Characterization of RNA-Binding Proteins Across Human Cancers. *Cell Rep*. 22 (1), 286–298. doi:10.1016/j.celrep.2017.12.035

Wende, W., Friedhoff, P., and Sträßer, K. (2019). Mechanism and Regulation of Co-transcriptional mRNP Assembly and Nuclear mRNA Export. *Adv. Exp. Med. Biol.*. 1203, 1–31. doi:10.1007/978-3-030-31434-7_1

Xu, L., Chen, Y., Mayakonda, A., Koh, L., Chong, Y. K., Buckley, D. L., et al. (2018). Targetable BET Proteins- and E2F1-Dependent Transcriptional Program Maintains the Malignancy of Glioblastoma. *Proc. Natl. Acad. Sci. USA*. 115 (22), E5086–E5095. doi:10.1073/pnas.1712363115

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 Mutations in Gliomas. *N. Engl. J. Med.*. 360 (8), 765–773. doi:10.1056/nejmoa0808710

Yi, C., Li, G., Ivanov, D. N., Wang, Z., Velasco, M. X., Hernández, G., et al. (2018). Luteolin Inhibits Musashi1 Binding to RNA and Disrupts Cancer Phenotypes in Glioblastoma Cells. *RNA Biol.* 15 (11), 1420–1432. doi:10.1080/15476286.2018.1539607

Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). ClusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. *OMICS: A J. Integr. Biol.*. 16 (5), 284–287. doi:10.1089/omi.2011.0118

Zhang, J., Xu, E., Ren, C., Yang, H. J., Zhang, Y., Sun, W., et al. (2018). Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN. *Cancer Res*. 78 (6), 1511–1521. doi:10.1158/0008-5472.can-17-2457

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sun, Pan, Mu, Ma, Shen and Long. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.